Literature DB >> 25389795

Gadolinium-associated plaques: a new, distinctive clinical entity.

Robert M Gathings1, Raveena Reddy2, Daniel Santa Cruz3, Robert T Brodell4.   

Abstract

IMPORTANCE: A new condition, gadolinium-associated plaques (GAP), is reported in 2 patients. It is related to a particular type of gadolinium (gadodiamide) used for contrast-enhanced radiologic studies. OBSERVATIONS: Erythematous plaques, 0.5 to 2.5 cm in diameter, were pruritic in one case and asymptomatic in a second case. Findings from the histopathologic examination revealed eosinophilic, collagenous, round or ovoid bodies (sclerotic bodies) in various stages of calcification. Previously, these sclerotic bodies were thought to be pathognomonic for nephrogenic systemic fibrosis (NSF) in the setting of chronic renal disease with associated gadolinium exposure. Neither patient had NSF, while only 1 of these patients had renal disease. The patient who did not have renal disease received high doses of gadolinium. CONCLUSIONS AND RELEVANCE: Physicians should be aware that GAP can occur without NSF or renal disease and is associated with the use of radiologic dyes. Sclerotic bodies have been reported only in association with gadolinium exposure (eg, gadodiamide) either in the sclerotic skin in NSF or in GAP.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25389795     DOI: 10.1001/jamadermatol.2014.2660

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  9 in total

1.  Brain Tumor-Enhancement Visualization and Morphometric Assessment: A Comparison of MPRAGE, SPACE, and VIBE MRI Techniques.

Authors:  L Danieli; G C Riccitelli; D Distefano; E Prodi; E Ventura; A Cianfoni; A Kaelin-Lang; M Reinert; E Pravatà
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-20       Impact factor: 3.825

2.  Comparative analysis of fluorescent angiography, computed tomographic angiography and magnetic resonance angiography for planning autologous breast reconstruction.

Authors:  Michael P Chae; David J Hunter-Smith; Warren Matthew Rozen
Journal:  Gland Surg       Date:  2015-04

Review 3.  Distribution and chemical forms of gadolinium in the brain: a review.

Authors:  Tomonori Kanda; Yudai Nakai; Akifumi Hagiwara; Hiroshi Oba; Keiko Toyoda; Shigeru Furui
Journal:  Br J Radiol       Date:  2017-09-28       Impact factor: 3.039

Review 4.  Gadolinium retention in the body: what we know and what we can do.

Authors:  Enrico Tedeschi; Ferdinando Caranci; Flavio Giordano; Valentina Angelini; Sirio Cocozza; Arturo Brunetti
Journal:  Radiol Med       Date:  2017-03-30       Impact factor: 3.469

5.  Gadolinium Deposition Disease: A Case Report and the Prevalence of Enhanced MRI Procedures Within the Veterans Health Administration.

Authors:  D Bradley Jackson; Terence MacIntyre; Vianey Duarte-Miramontes; Joshua DeAguero; G Patricia Escobar; Brent Wagner
Journal:  Fed Pract       Date:  2022-05-14

Review 6.  Brain gadolinium deposition after administration of gadolinium-based contrast agents.

Authors:  Tomonori Kanda; Hiroshi Oba; Keiko Toyoda; Kazuhiro Kitajima; Shigeru Furui
Journal:  Jpn J Radiol       Date:  2015-11-25       Impact factor: 2.374

7.  Safety assessment of gadolinium-based contrast agents (GBCAs) requires consideration of long-term adverse effects in all human tissues.

Authors:  Hans-Klaus Goischke
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-04-12

Review 8.  Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.

Authors:  Julie Davies; Petra Siebenhandl-Wolff; Francois Tranquart; Paul Jones; Paul Evans
Journal:  Arch Toxicol       Date:  2022-01-08       Impact factor: 5.153

Review 9.  Use of Real-Life Safety Data From International Pharmacovigilance Databases to Assess the Importance of Symptoms Associated With Gadolinium Exposure.

Authors:  Imran Shahid; Alvin Joseph; Eric Lancelot
Journal:  Invest Radiol       Date:  2022-04-26       Impact factor: 10.065

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.